NanoViricides Reports That The Phase I NV-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon
NanoViricides Reports That The Phase I NV-387 Clinical Trial Is Completed Successfully And Data Lock Is Expected Soon
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.